Myriad Genetics CEO Buys Nearly $200K in Stock Following Recent Financial Loss
MYGN sits 28% above its 52-week low of $3.76 on elevated volume (2.8× avg).
Summary
Myriad Genetics' President and CEO, Samraat S. Raha, purchased $199,844 worth of common stock in an open market transaction, signaling executive confidence after recent financial challenges.
Key Events · Ownership and Investor Activity · MYGN
-
CEO Stock Purchase
President and CEO Samraat S. Raha acquired 40,000 shares of common stock for a total of $199,844 at an average price of $5.00 per share, which is slightly above the current market price of $4.83.
-
Vote of Confidence Amidst Challenges
This purchase by a key executive follows the company's recent disclosure of a $365.9 million net loss and the filing of a $200 million universal shelf registration, suggesting executive belief in the company's prospects despite recent challenges.
Analysis · MYGN · Life Sciences
This open market purchase by President and CEO Samraat S. Raha signals a vote of confidence in Myriad Genetics, especially coming after the company reported a significant net loss and filed a universal shelf registration due to losing its 'well-known seasoned issuer' status. The CEO's decision to invest nearly $200,000 in company stock at an average price of $5.00 per share, slightly above the current market price of $4.83, suggests a belief in future recovery or undervaluation, potentially counteracting recent negative sentiment.
At the time of this filing, MYGN was trading at $4.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $449.8M. The 52-week trading range was $3.76 to $11.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.